Arcoma

Arcoma Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Arcoma (ARCOMA.ST) as of Oct 24, 2026 is 23.87. In the previous year, Cash Conversion Cycle (CCC) was 73.60 — a change of -67.57% (lower).

Cash Conversion Cycle

23.87

YoY

-67.57%

Last updated:

Cash Conversion Cycle (CCC) of Arcoma is 2025 23.87 . Cash Conversion Cycle (CCC) of Arcoma was 2024 73.60 . It decreases by -67.57% lower compared to the previous year.

The Arcoma Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
76.48 SEK
Jan 1, 2019
89.74 SEK
Jan 1, 2020
100.15 SEK
Jan 1, 2021
85.75 SEK
Jan 1, 2022
98.03 SEK
Jan 1, 2023
60.31 SEK
Jan 1, 2024
73.60 SEK
Jan 1, 2025
23.87 SEK
The Arcoma Cash Conversion Cycle history
YEARCash Conversion CycleYoY
23.87-67.57%
73.60+22.02%
60.31-38.47%
98.03+14.31%
85.75-14.38%
100.15+11.60%
89.74+17.35%
76.48-17.65%
92.87-7.90%
100.83+21.11%
83.26-0.19%
83.42—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

Cash Conversion Cycle (CCC) of Arcoma is 23.87 in 2025.

Cash Conversion Cycle (CCC) of Arcoma changed from 73.60 to 23.87, representing a -67.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Arcoma since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Arcoma with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Arcoma

All Key Metrics — Arcoma